U.S. markets closed

Anika Therapeutics, Inc. (ANIK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.38+0.64 (+2.94%)
At close: 04:00PM EDT
22.38 0.00 (0.00%)
After hours: 04:01PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close21.74
Bid15.80 x 900
Ask22.37 x 1400
Day's Range21.60 - 22.44
52 Week Range19.95 - 45.81
Avg. Volume101,617
Market Cap326.746M
Beta (5Y Monthly)1.00
PE Ratio (TTM)N/A
EPS (TTM)-0.12
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ANIK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Anika Therapeutics Inc.
    ANIK: What does Argus have to say about ANIK?ANIKA THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $24.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • Zacks

    Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates

    Anika (ANIK) delivered earnings and revenue surprises of 23.08% and 8.95%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Anika Reports Second Quarter Fiscal 2022 Financial Results

    Second quarter revenue growth up 4%X-Twist™ 510(k) clearance received; Limited market release on schedule for 2H 2022 BEDFORD, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its second quarter ended June 30, 2022. Second Quarter 2022 Financial Summary Revenue in the second quarter of 2022 was $39.7 million, up 4% compared with $38.1 million in the second

  • GlobeNewswire

    Anika Receives the ACE Award for Cutting-Edge Innovation for Tactoset® Injectable Bone Substitute from the American Orthopedic Society for Sports Medicine

    BEDFORD, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received the Accelerating the Cutting Edge (ACE) Award from the American Orthopaedic Society for Sports Medicine (AOSSM) for Tactoset® Injectable Bone Substitute for hardware augmentation. This award highlights the innovative nature of Tactoset, a calcium phosphate based, biocompatible bone graft subs